Tejnaksh Healthcare Limited has informed the exchanges that its board will meet on May 30, 2026, to consider and approve the audited financial results for the quarter and financial year ended March 31, 2026. The meeting is scheduled to take place at the company's registered office located in Jogeshwari East, Mumbai.

The agenda for the meeting includes the consideration and approval of the standalone and consolidated audited financial results. Additionally, the board will transact any other matter with the permission of the Chair.

In compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and a BSE circular issued in April 2019, the company had closed its trading window on March 27, 2026. This closure will remain in effect until the expiry of 48 hours after the declaration of the audited financial results for the quarter and year ended March 31, 2026.

Meeting Details

The intimation was signed by Dr. Ashish V. Rawandale, Managing Director of the company.

Tejnaksh Healthcare Limited has issued a formal response to the Bombay Stock Exchange (BSE) regarding a clarification sought on significant movement in the company's share price. The response, dated April 9, 2026, addresses concerns raised by the exchange about recent price volatility.

Company's Response to BSE Inquiry

The healthcare company received a clarification request from BSE on April 8, 2026, with reference number L/SURV/ONL/PV/APJ/2026-2027/3536. In its response, the company categorically stated that there is no material information or disclosure that has been withheld from stock exchanges in the recent past.

Regulatory Compliance Statement

Tejnaksh Healthcare emphasized its commitment to regulatory compliance, stating that it has been diligently disclosing all material information to various stakeholders. The company confirmed that it has been duly complying with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.

The management further assured that the company will continue to disclose any material information whenever required, maintaining transparency with investors and regulatory bodies.

Market-Driven Price Movement

Regarding the share price volatility that prompted the BSE inquiry, the company attributed the movement to prevailing market conditions. The management stated that the price movement is "purely due to market conditions and absolutely market driven," indicating no company-specific factors behind the recent fluctuations.

The response was signed by Dr. Ashish V. Rawandale, Managing Director (DIN: 02005733), who digitally authenticated the document on April 9, 2026, at 23:09:06 +05'30'.